Status: Recruiting
Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE)
The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)
Participants needed: 80
Trial details
Phase: Phase 2Age: 18-75Biological sex: AllType: InterventionalSponsor: Zura Bio IncUpdated: Feb 12, 2026Locations: 51
Eligibility criteria
Male or female, 18 to 75 years of age [+7]
Left ventricular failure [+8]